RxDoctor Payments Data

Vincent Wilson, MD

Family Medicine · Mount Olive, NCNPI 1609820463

Payments from drug & device makers

$11,036in general payments, 2019–2025

Across 725 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$890
  • Amgen$750
  • Pfizer$741
  • AbbVie$675
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$567
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,033100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk94$1,248
AstraZeneca48$890
Amgen61$750
Pfizer46$741
AbbVie63$675
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC47$567
Bayer28$477
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$433
Merck19$365
Boehringer Ingelheim19$324
GSK18$272
E.r. Squibb & Sons, L.L.C.16$247
Otsuka America Pharmaceutical, Inc.12$243
Amarin Pharma, Inc.14$229
Astellas Pharma US Inc9$208
Takeda Pharmaceuticals U.S.A., Inc.13$205
Lilly USA, LLC12$172
Sumitomo Pharma America, Inc.9$166
Scilex Pharmaceuticals Inc.9$145
Nestle Healthcare Nutrition Inc.7$142
Phathom Pharmaceuticals, Inc.7$140
Lundbeck LLC7$138
Abbott8$133
Ironwood Pharmaceuticals, Inc9$127
Novartis8$127
Sanofi-aventis U.S. LLC9$127
Upsher-smith Laboratories LLC8$123
Corcept Therapeutics6$120
Eisai Inc.9$115
Biohaven Pharmaceutical Holding Company Ltd.6$114
Arbor Pharmaceuticals, Inc.8$110
Esperion Therapeutics, Inc.5$98
Johnson & Johnson7$95
Jazz Pharmaceuticals Inc.5$88
Teva Pharmaceuticals USA, Inc.5$77
Axsome Therapeutics, Inc.4$76
Biohaven Pharmaceuticals, Inc.4$68
Aimmune Therapeutics, Inc.3$62
Exact Sciences3$52
Daiichi Sankyo Inc.3$52
Kowa Pharmaceuticals America, Inc.4$49
Vivus LLC3$49
Seqirus USA Inc2$46
Bausch Health US, LLC2$36
Azurity Pharmaceuticals, Inc.2$35
Tolmar, Inc.2$31
Idorsia Pharmaceuticals US Inc2$27
Sanofi Pasteur Inc.2$26
Medtronic1$22
Ironshore Pharmaceuticals Inc.1$21
Cranial Technologies, Inc1$20
Scynexis, Inc.1$18
Ardelyx, Inc.1$16
Dexcom, Inc.1$15
Mylan Specialty L.p.1$15
Nabriva Therapeutics, PLC1$14
Almatica Pharma LLC1$14
Sunovion Pharmaceuticals Inc.1$13
Amneal Pharmaceuticals LLC1$12
Radius Health, Inc.1$11

How this compares

$11,036 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$148,535
Medicare patients
429
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$125,413
EliquisApixaban141$110,028
KerendiaFinerenone115$100,110
JardianceEmpagliflozin79$79,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$66,626
FarxigaDapagliflozin Propanediol86$65,131
XareltoRivaroxaban38$34,187
Repatha SureclickEvolocumab47$30,733
Victoza 3-PakLiraglutide19$25,563
JanuviaSitagliptin Phosphate23$23,542
RybelsusSemaglutide26$20,177
JanumetSitagliptin Phos/Metformin Hcl19$19,203
MounjaroTirzepatide12$16,850
FycompaPerampanel12$14,807
LinzessLinaclotide11$14,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,248$145,590139 claims
PfizerEliquis$741$110,028141 claims
BayerKerendia$477$100,110115 claims
Boehringer IngelheimJardiance$324$79,02879 claims
GSKTrelegy Ellipta, Breo Ellipta$272$74,49773 claims
AstraZenecaFarxiga$890$65,13186 claims
MerckJanuvia, Janumet, Janumet Xr$365$55,64857 claims
Johnson & JohnsonXarelto, Invokana$95$46,96150 claims
AbbVieLinzess, Synthroid$675$18,32240 claims
Lilly USA, LLCMounjaro$172$16,85012 claims
Eisai Inc.Fycompa$115$14,80712 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$110$10,93136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Mount Olive

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →